Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.

导出 OA

翻译打印收藏纠错

第一作者： Francesco,Passiglia

第一单位： Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy.

作者： Francesco,Passiglia ^[1] ; Antonio,Galvano ^[1] ; Marta,Castiglia ^[1] ; Lorena,Incorvaia ^[1] ; Valentina,Calò ^[1] ; Angela,Listì ^[1] ; Salvatore,Mazzarisi ^[2] ; Alessandro,Perez ^[1] ; Giuseppe,Gallina ^[1] ; Sergio,Rizzo ^[1] ; Hector,Soto Parra ^[2] ; Viviana,Bazan ^[1] ; Antonio,Russo ^[3]

作者单位： Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy. ^[1] Medical Oncology Unit, AOU Policlinico Vittorio Emanuele, Catania, Italy. ^[2] Department of Oncology, A.O.U.P. 'P. Giaccone' University Hospital, 2013 ESMO Designated Centres of Integrated Oncology and Palliative Care, Via del Vespro 129, 90127 Palermo, Italy. ^[3]

关键词 Circulating free DNA (cfDNA)blood-based biomarkers immunotherapy neutrophil to lymphocyte ratio (NLR)non-small cell lung cancer (NSCLC)

DOI 10.1177/1758835919839928

PMID 31019571

发布时间 2022-04-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览12

Therapeutic advances in medical oncology

2019年11卷

1758835919839928页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.

Therapeutic advances in medical oncology

相似文献

Therapeutic advances in medical oncology

相关期刊

检索历史清除